Conclusions
TAPSE may be one of the independent significant predictors of CV events
in patients with MR undergoing MitraClip therapy. TAPSE may be measured
prior to MitraClip therapy as a simple and easy parameter of RV function
to predict worse outcomes in a MitraClip cohort.